Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

  • 47 Accesses

  • 37 Citations

Summary

The influence of plasma estrogen levels on disease-free interval (time from primary treatment to first relapse, DFI) in breast cancer patients is not known. Any relation between plasma estrogens and the outcome in breast cancer patients may have implications considering use of hormone replacement therapy (HRT) in patients treated for breast cancer. We measured plasma estradiol (E2), estrone (E1), and estrone sulfate (E1S) in 92 postmenopausal women with breast cancer relapse and correlated plasma estrogen levels to the length of their disease-free interval (DFI1) and the length of the DFI in the subgroup of patients in whom this extended a time period of more than 2 years (DFI2). The length of DFI2 correlated negatively to plasma level of E1S (p < 0.025) and E2 (p < 0.05) and to the E2/E1 and E1S/E1 ratios (p < 0.05), while the length of DFI1 correlated negatively to plasma level of E1S (p < 0.025) and the E1S/E1 ratio (p < 0.005). We also analyzed for possible correlations between DFIs and plasma estrogen levels in subgroups based on tumor stage at diagnosis and previous therapy. In general, these subgroup analyses revealed negative correlations of statistical significance or borderline significance between the DFI1 and DFI2 and E2 and the E2/E1 ratio and non-significant negative correlations between plasma levels of E1S and DFI1 and DFI2. In particular, strong negative correlations between plasma estrogen levels and the length of DFI1 and DFI2 were found among patients responding to first line endocrine treatment for relapse and among patients with primar stage III tumors. Our findings suggest plasma E2 and E1S to stimulate the growth of micrometastases in patients treated for breast cancer.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104–107, 1896

  2. 2.

    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127–205, 1984

  3. 3.

    Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221–265, 1990

  4. 4.

    Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC: Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 10: 1547–1552, 1992

  5. 5.

    Early Breast Cancer Trialist Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Lancet 339: 1–15, 1992

  6. 6.

    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016–1037, 1992

  7. 7.

    Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC: Estrogen replacement therapy in breast cancer survivors. J Am Med Assoc 272: 540–545, 1994

  8. 8.

    Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190–197, 1995

  9. 9.

    Rose C, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brünner N, Kjaer M, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2: 395–400, 1982

  10. 10.

    Lønning PE, Helle S-I, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 42: 23–30, 1995

  11. 11.

    Fotsis T, Adlercreutz H: The multicomponent analysis of oestrogens in urine by ion exchange chromatography GCMS. I. Quantitation of oestrogens after initial hydrolysis of conjugates. J Steroid Biochem 28: 203–213, 1987

  12. 12.

    Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hämäläinen E: Estrogen metabolism and excretion in oriental and caucasian women. J Natl Cancer Inst 86: 1076–1082, 1994

  13. 13.

    Lønning PE, Lien EA, Lundgren S, Kvinnsland S: Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22: 327–358, 1992

  14. 14.

    Fracchia AA, Farrow JH, DePalo AJ, Connolly DP, Huvos AG: Castration for primary inoperable or recurrent breast carcinoma. Surg Gyn Obstet 128: 1226–1234, 1969

  15. 15.

    Høst H, Lund E: Age as a prognostic factor in breast cancer. Cancer 57: 2217–2221, 1986

  16. 16.

    Gambrell DR: Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynecol 150: 119–128, 1984

  17. 17.

    Vassilopoulou-Sellin R, Theriault RL: Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 16: 153–159, 1994

  18. 18.

    Langlands AO, Pocock SJ, Kerr GR, Gore SM: Long-term survival of patients with breast cancer: a study of the curability of the disease. Brit Med J 2: 1247–1251, 1979

  19. 19.

    Eberlein T, Simon R, Fisher S, Lippman ME: Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat 5: 81–86, 1985

  20. 20.

    Santner SJ, Feil PD, Santen RJ:In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59: 29–33, 1984

  21. 21.

    Tait GH, Newton CJ, Reed MJ, James VHT: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. J Molec Endocr 2: 71–80, 1989

  22. 22.

    Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J: Abormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79: 3047–3051, 1982

  23. 23.

    De Nosaquo N: Androgens and estrogens in the treatment of disseminated mammary cancer. J Am Med Assoc 172: 1271–1283, 1960

Download references

Author information

Correspondence to Per E. Lønning.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lønning, P.E., Helle, S.I., Johannessen, D.C. et al. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Tr 39, 335–341 (1996). https://doi.org/10.1007/BF01806162

Download citation

Key words

  • breast cancer
  • disease-free interval
  • estrogens